Total Payments
$970,450
2024 Payments
$254,619
Companies
55
Transactions
2,573
Medicare Patients
8,717
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$724,431 (74.6%)
Consulting$123,667 (12.7%)
Food & Beverage$63,297 (6.5%)
Travel$48,600 (5.0%)
Research$9,385 (1.0%)
Education$1,069 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $702,531 | 241 | 72.4% |
| Consulting Fee | $123,667 | 45 | 12.7% |
| Food and Beverage | $63,297 | 1,911 | 6.5% |
| Travel and Lodging | $48,600 | 333 | 5.0% |
| Honoraria | $13,800 | 8 | 1.4% |
| Unspecified | $9,385 | 5 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $8,100 | 5 | 0.8% |
| Education | $1,069 | 25 | 0.1% |
Payments by Type
General
$961,064
2,568 transactions
Research
$9,385
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $166,003 | 435 | $0 (2024) |
| UCB, Inc. | $107,233 | 162 | $0 (2024) |
| Amgen Inc. | $98,874 | 183 | $0 (2024) |
| Janssen Biotech, Inc. | $87,167 | 236 | $0 (2024) |
| Arcutis Biotherapeutics, Inc. | $84,672 | 97 | $0 (2024) |
| PFIZER INC. | $79,315 | 228 | $0 (2024) |
| Incyte Corporation | $51,598 | 91 | $0 (2024) |
| Celgene Corporation | $43,583 | 96 | $0 (2019) |
| LEO Pharma Inc. | $39,997 | 81 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $36,268 | 60 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $254,619 | 472 | Arcutis Biotherapeutics, Inc. ($40,579) |
| 2023 | $197,193 | 420 | Arcutis Biotherapeutics, Inc. ($44,094) |
| 2022 | $130,794 | 345 | ABBVIE INC. ($30,585) |
| 2021 | $103,223 | 279 | Amgen Inc. ($33,989) |
| 2020 | $45,437 | 207 | Amgen Inc. ($12,731) |
| 2019 | $104,714 | 380 | UCB, Inc. ($25,763) |
| 2018 | $71,298 | 238 | PFIZER INC. ($22,855) |
| 2017 | $63,173 | 232 | AbbVie, Inc. ($26,191) |
All Payment Transactions
2,573 individual payment records from CMS Open Payments — Page 1 of 103
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $12.66 | General |
| 12/20/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $121.20 | General |
| Category: DERMATOLOGY | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| Category: Immunology | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $8.24 | General |
| Category: Immunology | ||||||
| 12/20/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $4.16 | General |
| Category: Dermatology | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $1,632.37 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $474.56 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $396.05 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $37.25 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $9.76 | General |
| Category: Inflammation | ||||||
| 12/18/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $7.44 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $5.26 | General |
| Category: Inflammation & Immunology | ||||||
| 12/16/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $30.11 | General |
| Category: Immunology | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $4.35 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $9.23 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $3.46 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $2.26 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $6.38 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/05/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES) | Almirall LLC | $8,037 | 2 |
| Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis (PSOR-025) | Amgen Inc. | $1,121 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 2,165 | 4,900 | $616,975 | $254,309 |
| 2022 | 9 | 2,156 | 4,960 | $629,170 | $263,785 |
| 2021 | 12 | 2,224 | 5,595 | $691,580 | $305,200 |
| 2020 | 13 | 2,172 | 5,272 | $584,508 | $206,151 |
Total Patients
8,717
Total Services
20,727
Medicare Billing
$1.0M
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 660 | 1,318 | $257,010 | $118,255 | 46.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 359 | 532 | $93,100 | $46,062 | 49.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 211 | 211 | $53,805 | $23,396 | 43.5% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 91 | 150 | $56,250 | $19,894 | 35.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 368 | 527 | $60,605 | $18,968 | 31.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 301 | 1,964 | $39,280 | $9,807 | 25.0% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 57 | 65 | $24,375 | $6,453 | 26.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 89 | 100 | $21,000 | $6,122 | 29.2% |
| 10061 | Complicated or multiple drainage of skin abscess | Office | 2023 | 29 | 33 | $11,550 | $5,352 | 46.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 633 | 1,325 | $258,375 | $121,148 | 46.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 377 | 551 | $96,425 | $48,094 | 49.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 222 | 222 | $56,610 | $25,144 | 44.4% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 94 | 151 | $56,625 | $20,007 | 35.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 360 | 523 | $60,145 | $18,751 | 31.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 283 | 1,968 | $39,360 | $10,081 | 25.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 98 | 117 | $23,680 | $8,027 | 33.9% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2022 | 63 | 76 | $28,500 | $7,990 | 28.0% |
| 10061 | Complicated or multiple drainage of skin abscess | Office | 2022 | 26 | 27 | $9,450 | $4,542 | 48.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 623 | 1,456 | $283,920 | $141,244 | 49.7% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 363 | 573 | $100,275 | $50,901 | 50.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 236 | 236 | $60,180 | $27,738 | 46.1% |
| 17000 | Destruction of skin growth | Office | 2021 | 357 | 569 | $65,340 | $22,010 | 33.7% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 96 | 144 | $54,000 | $18,821 | 34.9% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 295 | 2,259 | $45,750 | $12,174 | 26.6% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 121 | 149 | $26,360 | $10,821 | 41.0% |
About Dr. Harry Greenberg, MD
Dr. Harry Greenberg, MD is a Dermatology healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447276175.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harry Greenberg, MD has received a total of $970,450 in payments from pharmaceutical and medical device companies, with $254,619 received in 2024. These payments were reported across 2,573 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($702,531).
As a Medicare-enrolled provider, Greenberg has provided services to 8,717 Medicare beneficiaries, totaling 20,727 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties MOHS-Micrographic Surgery, Procedural Dermatology
- Location Las Vegas, NV
- Active Since 07/14/2006
- Last Updated 08/07/2013
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1447276175
Products in Payments
- Otezla (Drug) $129,480
- TREMFYA (Drug) $112,880
- SKYRIZI (Biological) $82,739
- DUPIXENT (Biological) $60,305
- EUCRISA (Drug) $58,575
- OPZELURA (Drug) $51,466
- Cimzia (Drug) $43,600
- Bimzelx (Biological) $41,143
- Zoryve (Drug) $40,579
- ADBRY (Biological) $39,304
- Humira (Biological) $35,028
- RINVOQ (Biological) $15,587
- ILUMYA (Biological) $14,927
- CIBINQO (Drug) $11,105
- DUOBRII (Drug) $9,275
- VTAMA (Drug) $8,998
- Seysara (Drug) $8,320
- Skyrizi (Biological) $8,316
- Finacea (Drug) $7,727
- Ilumya (Biological) $7,662
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Las Vegas
Mrs. Miriam Bettencourt, Md, MD
Dermatology — Payments: $1.2M
Dermatology $1.2M
Dr. David Cotter, Md, Phd, MD, PHD
Dermatology — Payments: $703,353
Dermatology $703,353
Dr. Robert Strimling, Md, MD
Dermatology — Payments: $76,428
Dermatology $76,428
Dr. Candace Spann, M.d, M.D
Dermatology — Payments: $26,803
Dermatology $26,803
Dr. Clifton Hall, M.d, M.D
Dermatology — Payments: $17,129
Dermatology $17,129
Ms. Susun Michaels, Do, DO
Dermatology — Payments: $14,336
Dermatology $14,336